The longevity industry is predicted to grow to $600 Billion by 2025, according to Bank of America Merril Lynch. The longevity revolution could result in radical life extension that “disrupts death”, according to the bank’s strategists.

Sebastian A. Brunemeier is a biomedical scientist, biotech VC, and Oxford alumnus with extensive experience in anti-ageing drug discovery and investing. He is the co-founder of Cambrian Biopharma, a drug discovery company focused on the biology of ageing and founder of Samsara Therapeutics, a biotech focused on small molecule drug discovery. He has served as a principal investor for Apollo Ventures, the largest ageing-focused VC fund in the world, and an advisor to McKinsey & Company. Prior to his professional career, Sebastian was a Fulbright Fellow at the Gulbenkian Institute, a Skaggs-Oxford Scholar at the Scripps Research Institute, and a SENS Foundation Scholar at the Buck Institute.